Adverse events of intravenous immunoglobulin infusions: a three-year retrospective study in China

doi:10.5246/jcps.2019.01.007

Journal of Chinese Pharmaceutical Sciences ›› 2019, Vol. 28 ›› Issue (1): 56-61.DOI: 10.5246/jcps.2019.01.007

• Drug administration and clinical pharmacy column • Previous Articles Next Articles

Adverse events of intravenous immunoglobulin infusions: a three-year retrospective study in China

Shurong Shao^1*, Wei Guo^2,3

1. Pharmaceutical department, Ningbo Women & Children’s Hospital, Ningbo 315012, China
2. Molecular Neuropharmacology Laboratory, School of Optometry and Ophthalmology and Eye Hospital, Wenzhou Medical University, Wenzhou 325035, China
3. State Key Laboratory Cultivation Base and Key Laboratory of Vision Science, Ministry of Health, China and Zhejiang Provincial Key Laboratory of Ophthalmology and Optometry, Wenzhou 325035, China

Received:2018-10-07 Revised:2018-11-12 Online:2019-01-27 Published:2018-12-05
Contact: Tel.: +86-0574-83887054, E-mail: shaoshurong1988@163.com
Supported by:
Wenzhou Science and Technology Program (Grant No. Y20160012).

Abstract

Abstract:

Intravenous immunoglobulin (IVIG) is biological product, which is extensively used in pediatric patients, with high adverse effects on children among different brand preparations. In the present study, we aimed to describe the adverse events of pediatric patients given IVIG infusions in China. Data were collected from all patients receiving IVIG infusion at the largest children’s hospital in Ningbo of China form January 2015 to December 2017. Descriptive statistics was used. A total of 2100 patients received IVIG infusion. All the patients who experienced adverse reactions were children (0.48%), with the highest frequency of infusion among those age 1 to 3 years old (40%). Among 10 infusions with adverse reactions, the most common indication was Kawasaki disease (40%) followed by severe pneumonia (30%). Rash was the most common adverse event (80%), followed by chest pain & cough (50%) and cyanosis (40%). Adverse events were observed to occur most frequently within 30 min from onset of infusion. Most of the reactions occurred with the large dose and the indications of used for. Since the hospital changed the brand, the incidence of adverse reactions was decreased from 1.39% to 0.13%.In this study, 0.48% of pediatric patients given IVIG infusions experienced adverse events. Anaphylactoid reaction was the most common manifestation. Symptoms occurred within 30 min from onset of infusion, which were affected by the dose, the value of lgE, the indications and the different brands.

Key words: Intravenous immunoglobulin, Adverse reactions, Children, Retrospective study

CLC Number:

R969

Supporting:

Shurong Shao, Wei Guo. Adverse events of intravenous immunoglobulin infusions: a three-year retrospective study in China[J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(1): 56-61.

References

[1] Sewell, W.A.; Jolles, S. Immunomodulatory action of intravenous immunoglobulin. Immunology. 2002, 107, 387-393.

[2] Diep, B.A.; Le, V.T.; Badiou, C.; Le, H.N.; Pinheiro, M.G.; Duong, A.H.; Wang, X.; Dip, E.C.; Aguiar-Alves, F.; Basuino, L.; Marbach, H.; Mai, T.T.; Sarda, M.N.; Kajikawa, O.; Matute-Bello, G.; Tkaczyk, C.; Rasigade, J.P.; Sellman, B.R.; Chambers, H.F.; Lina, G. IVIG-mediated protection against necrotizing pneumonia caused by MRSA. Sci. Transl. Med. 2016, 8, 357ra124.

[3] Burns, J.C.; Franco, A. The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease. Expert Rev. Clin. Immunol. 2015, 11, 819-825.

[4] Choi, H.S.; Ji, M.H.; Kim, S.J.; Ahn, H.S. Platelet count recovery after intravenous immunoglobulin predicts a favorable outcome in children with immune thrombocytopenia. Blood Res. 2016, 51, 95-101.

[5] Brenton, J.N.; Banwell, B.L. Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis. Neurotherapeutics. 2016, 13, 84-95.

[6] Palabrica, F.R.; Kwong, S.L.; Padua, F.R. Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective study. Asia Pac. Allergy. 2013, 3, 249-256.

[7] Wada, Y.; Kamei, A.; Fujii, Y.; Ishikawa, K.; Chida, S. Cerebral infarction after high-dose intravenous immuno-globulin therapy for Kawasaki disease. J. Pediatr. 2006, 148, 399-400.

[8] Kahwaji, J.; Barker, E.; Pepkowitz, S.; Klapper, E.; Villicana, R.; Peng, A.; Chang, R.; Jordan, S.C.; Vo, A.A. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. Clin. J. Am. Soc. Nephrol. 2009, 4, 1993-1997.

[9] Alliot, C.; Rapin, J.P.; Besson, M.; Bedjaoui, F.; Messouak, D. Pulmonary embolism after intravenous immunoglobulin. J. R. Soc. Med. 2001, 94, 187-188.

[10] Dalakas, M.C. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology. 1994, 44, 223-226.

[11] Siegel, J. The product: All intravenous immunoglobulins are not equivalent. Pharmacotherapy. 2005, 25, S78-S84.

[12] Singh-Grewal, D.; Kemp, A.; Wong, M. A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions. Arch. Dis. Child. 2006, 91, 651-654.

[13] Yi, Z.M.; Tang, S.D.; Liu, F.; Zhai, S.D.; Jiao, L.G. Evaluation on telbivudine-associated rhabdomyolysis. J. Chin. Pharm. Sci. 2016, 25, 66-72.

Adverse events of intravenous immunoglobulin infusions: a three-year retrospective study in China

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 4

Recommended Articles

Metrics

Comments

[1]	Haiyan Wu, Xiang Zhang, Shanshan Ding, Guohua Zhang, Linlin Tang, Lin Tang. Progression of anti-mycoplasma drug therapy in children with refractory mycoplasma pneumonia [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(5): 334-342.
[2]	Yingyan Yan, Peizhi Mao, Yi Chen, Longhui Shen. Analysis of alternation with ibuprofen and acetaminophen in outpatient and emergency departments of a children’s hospital [J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(5): 369-373.
[3]	Jingjing Cao, Jun Sun, Shujuan Zhao, Peizhi Ma. Pharmacological and clinical evaluation of a new anti-flu drug, baloxavir marboxil [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(10): 729-733.
[4]	http://www.fda.gov. Information from US FDA [J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(10): 724-731.